

(criteria for the evaluation of quantitative results)

| EQA programme | | | EQA programme | | | EQA programme | | |
|---|--------------|------------------|--|------|------------------|---|--------------|------------------|
| Test | | D _{max} | Test | | D _{max} | Test | | D _{max} |
| Folate | | | RFA: Risk Factors for Atherosclerosis | | | hCG | | |
| to 5 nmol/L: | 1,35 nmol/L | | Apolipoprotein A1 | 17 % | | to 8 U/L: | 1,44 U/L | |
| from 5 nmol/L: | 27 % | | Apolipoprotein B | 14 % | | from 8 U/L: | 18 % | |
| LH | 15 % | | Cholesterol | 8 % | | Calcitonin | | 31 % |
| Parathyrin biointact (PTH 1-84) | | | Cholesterol HDL | 15 % | | NSE | | |
| to 1,2 pmol/L: | 0,276 pmol/L | | Cholesterol LDL (direct | 20 % | | to 3 µg/L: | 0,9 µg/L | |
| from 1,2 pmol/L: | 23 % | | determination) | | | from 3 µg/L: | 30 % | |
| Parathyrin intact (PTH) | | | Cholesterol LDL (calculation) | 15 % | | p2PSA | | 15 % |
| to 1,2 pmol/L: | 0,276 pmol/L | | Lipoprotein (a) [g/L] | 25 % | | PSA | | |
| from 1,2 pmol/L: | 23 % | | Lipoprotein (a) [nmol/L] | 20 % | | to 0,7 µg/L: | 0,105 µg/L | |
| Prolactin | | | Triacylglycerols | 13 % | | from 0,7 µg/L: | 15 % | |
| to 110 mU/L: | 17,6 mU/L | | TDM: Therapeutic Drugs | | | free-PSA | | |
| from 110 mU/L: | 16 % | | Digoxin | C | 30 % | to 0,7 µg/L: | 0,112 µg/L | |
| Renin | 20 % | | | T | 36 % | from 0,7 µg/L: | 16 % | |
| SHBG | 20 % | | Ethosuximide | | 24 % | S-100 | | |
| Vitamin B ₁₂ | 20 % | | Phenobarbital | | 20 % | to 0,04 µg/L: | 0,013 µg/L | |
| FOB: Faecal Occult Blood | | | Phenytoin | | 20 % | from 0,04 µg/L: | 32 % | |
| Haemoglobin | | 25 % | Carbamazepin | | 20 % | SCCA | | |
| GHP: Glycated Haemoglobin POCT | | | Valproic acid | | 20 % | to 0,8 µg/L: | 55 % | |
| Haemoglobin A _{1c} | C | 10 % | Lithium | C | 12 % | from 0,8 µg/L: | 32 % | |
| | T | 11 % | | T | 12 % | TPA | | |
| GLC: Glucose (Including Glucometers) | | | Primidone | | 24 % | to 50 U/L: | 12,5 U/L | |
| Glucose (laboratory systems) | C | 10 % | Theophylline | C | 19 % | from 50 U/L: | 25 % | |
| | T | 15 % | | T | 24 % | Thyreoglobulin | | 30 % |
| Glucose (Abbott POCT) | | | Amicacin | | 20 % | VVV: Maternal Diagnostic Screening (Triple | | |
| to 5,55 mmol/L: | 0,833 mmol/L | | Gentamicin | | 31 % | Test) | | |
| from 5,55 mmol/L: | 15 % | | Methotrexate | | 30 % | free β-hCG | | 15 % |
| Glucose (ACON POCT) | | | Vankomycin | | 28 % | PAPP-A | | |
| to 5,55 mmol/L: | 0,833 mmol/L | | TE: Trace Elements | | | to 0,1 U/L: | 0,015 U/L | |
| from 5,55 mmol/L: | 15 % | | Al - plasma | | 25 % | from 0,1 U/L: | 15 % | |
| Glucose (Arkray POCT) | | | Co - plasma | | 25 % | PIGF | | 23 % |
| to 5,55 mmol/L: | 0,833 mmol/L | | Cr - plasma | | 25 % | AFP | | 20 % |
| from 5,55 mmol/L: | 15 % | | Cu - plasma | | 25 % | hCG | | 18 % |
| Glucose (Ascensia POCT) | | | Mg - plasma | | 25 % | Estriol unconjug. | | |
| to 5,55 mmol/L: | 0,833 mmol/L | | Mn - plasma | | 25 % | to 0,8 nmol/L: | 0,264 nmol/L | |
| from 5,55 mmol/L: | 15 % | | Se - plasma | | 25 % | from 0,8 nmol/L: | 33 % | |
| Glucose (ForaCare POCT) | | | Zn - plasma | | 25 % | | | |
| to 5,55 mmol/L: | 0,833 mmol/L | | Cd - blood | | 25 % | | | |
| from 5,55 mmol/L: | 15 % | | Hg - blood | | 25 % | | | |
| Glucose (Infopia POCT) | | | Mn - blood | | 25 % | | | |
| to 5,55 mmol/L: | 0,833 mmol/L | | Pb - blood | | 25 % | | | |
| from 5,55 mmol/L: | 15 % | | Al - urine | | 25 % | | | |
| Glucose (LifeScan POCT) | | | Cd - urine | | 25 % | | | |
| to 5,55 mmol/L: | 0,833 mmol/L | | Cr - urine | | 25 % | | | |
| from 5,55 mmol/L: | 15 % | | Cu - urine | | 25 % | | | |
| Glucose (MED TRUST POCT) | | | Hg - urine | | 25 % | | | |
| to 5,55 mmol/L: | 0,833 mmol/L | | I - urine | | 25 % | | | |
| from 5,55 mmol/L: | 15 % | | Mn - urine | | 25 % | | | |
| Glucose (Nova POCT) | | | Ni - urine | | 25 % | | | |
| to 5,55 mmol/L: | 0,833 mmol/L | | Pb - urine | | 25 % | | | |
| from 5,55 mmol/L: | 15 % | | Se - urine | | 25 % | | | |
| Glucose (Roche POCT) | | | Zn - urine | | 25 % | | | |
| to 5,55 mmol/L: | 0,833 mmol/L | | TM: Tumour Markers | | | | | |
| from 5,55 mmol/L: | 15 % | | β-2-microglobulin | | 21 % | | | |
| HIL: Serum Indices | | | AFP | | | | | |
| Hemolytic index (quantitative) | | 20 % | to 10 µg/L: | | 2 µg/L | | | |
| Icteric index (quantitative) | | 20 % | from 10 µg/L: | | 20 % | | | |
| Lipemic index (quantitative) | | 20 % | CA 15-3 | | 18 % | | | |
| KD: Glycated Haemoglobin | | | CA 19-9 | | | | | |
| Haemoglobin A _{1c} | C | 10 % | to 14 kU/L: | | 2,8 kU/L | | | |
| | T | 11 % | from 14 kU/L: | | 20 % | | | |
| KM: Cardiac Markers | | | CA 72-4 | | 22 % | | | |
| CK-MB mass | | 27 % | CA 125 | | | | | |
| Homocysteine | | 20 % | to 10 kU/L: | | 2 kU/L | | | |
| Myoglobin | | 22 % | from 10 kU/L: | | 20 % | | | |
| NT-proBNP | | 27 % | CEA | | 16 % | | | |
| Troponin I | | | CYFRA 21-1 | | | | | |
| to 10 ng/L: | 2,7 ng/L | | to 1,3 µg/L: | | 0,234 µg/L | | | |
| from 10 ng/L: | 27 % | | from 1,3 µg/L: | | 18 % | | | |
| Troponin T | | 22 % | | | | | | |

(criteria for the evaluation of quantitative results)

| EQA programme Test | D _{max} | EQA programme Test | D _{max} | EQA programme Test | D _{max} |
|--------------------------------------|------------------|---|-----------------------------|--------------------------|------------------|
| Haematology | | Prothrombin test (Xprecia) | | 20 % | |
| AP: Antithrombotic Agents | | KO: Blood Count | | | |
| Apixaban | 25 % | WBC | | | |
| Dabigatran | 30 % | | to 4 ·10 ⁹ /L: | 18 % | |
| Rivaroxaban | 25 % | | from 4 ·10 ⁹ /L: | 15 % | |
| DD: D Dimers | | RBC | | 7 % | |
| D Dimers (FEU) | | Haemoglobin | | 6 % | |
| to 0,7 mg/L FEU: | 0,189 mg/L | HCT | | 10 % | |
| | FEU | MCV | | 10 % | |
| from 0,7 mg/L FEU: | 27 % | RDW | | 10 % | |
| D Dimers (DDim) | | Platelets | | 18 % | |
| to 0,3 mg/L D Dimer: | 0,081 mg/L D | MPV | | 18 % | |
| | Dimer | Immature platelet fraction | | 40 % | |
| from 0,3 mg/L D Dimer: | 27 % | PDW [%] | | 15 % | |
| HKG: Haemocoagulation Tests | | PDW [fL] | | 15 % | |
| Antithrombin | | PDW [-] | | 15 % | |
| to 50 %: | 25 % | Neutrophiles | | 25 % | |
| from 50 %: | 18 % | Lymphocytes | | 25 % | |
| APTT - ratio | 20 % | Monocytes | | 50 % | |
| Fibrinogen | 25 % | Eosinophils | | 50 % | |
| Prothrombin test (INR) | 20 % | Basophiles | | 100 % | |
| Prothrombin test (ratio) | 20 % | LMWH: Low Molecular Weight Heparin | | | |
| Thrombin time (time) | 15 % | Low Molecular Weight Heparin | | 25 % | |
| Thrombin time (ratio) | 20 % | RET: Reticulocytes | | | |
| HS: Haemocoagulation Special | | Reticulocyte count (analyser) | | 40 % | |
| Factor VIII | | Reticulocyte count (microscope) | | 45 % | |
| to 5 %: | 1,25 % | Immature reticulocyte fraction | | 45 % | |
| from 5 %: | 25 % | Mean amount of hemoglobin in reticulocytes | | 10 % | |
| von Willebrand f. (activity) | 25 % | Mean reticulocyte volume | | 10 % | |
| von Willebrand f. (antigen) | 20 % | SED: Erythrocyte Sedimentation Rate | | | |
| Factor IX | | Erythrocyte sedimentation (1 h) | | | |
| to 5 %: | 1,25 % | to 10 mm/1hour: | 5 mm/1hour | | |
| from 5 %: | 25 % | from 10 mm/1hour: | 50 % | | |
| Factor XI | 25 % | Erythrocyte sedimentation (2 h) | | | |
| Factor XII | | to 10 mm/2hours: | 5 mm/2hours | | |
| to 5 %: | 1,25 % | from 10 mm/2hours: | 50 % | | |
| from 5 %: | 25 % | | | | |
| Protein C | 20 % | | | | |
| Protein S | | | | | |
| to 10 %: | 3 % | | | | |
| from 10 %: | 30 % | | | | |
| ProC Global (norm. ratio) | 25 % | | | | |
| Factor II | 25 % | | | | |
| Factor V | 25 % | | | | |
| Factor VII | 25 % | | | | |
| Factor X | 25 % | | | | |
| INRP: INR measurement on POCT | | | | | |
| Prothrombin test (CoaguChek) | 20 % | | | | |
| Prothrombin test (microINR) | 20 % | | | | |
| | | Immunology | | | |
| | | CD34: Population of CD34+ Cells | | | |
| | | CD 34+ (absolute count) | | | |
| | | to 5 ·10 ⁶ /L: | | 1,25 ·10 ⁶ /L | |
| | | from 5 ·10 ⁶ /L: | | 25 % | |
| | | CD 34+ (relative count) | | | |
| | | to 0,1 %: | | 0,025 % | |
| | | from 0,1 %: | | 25 % | |
| | | WBC | | 15 % | |
| | | GP: Detection of Monoclonal Components | | | |
| | | Total protein (plasma) | | 8 % | |
| | | FLC kappa (plasma) | | | |
| | | to 6 mg/L: | | 3 mg/L | |
| | | from 6 mg/L: | | 50 % | |
| | | FLC lambda (plasma) | | | |
| | | to 6 mg/L: | | 3 mg/L | |
| | | from 6 mg/L: | | 50 % | |
| | | Index kappa/lambda | | 25 % | |
| | | Total protein (urine) | | 30 % | |
| | | IFT: Immunophenotypisation | | | |
| | | T lymphocytes (CD3+) | | 7 % | |
| | | Th lymphocytes (CD4+) | | 10 % | |
| | | T lymphocytes (CD8+) | | 17 % | |
| | | B lymphocytes | | | |
| | | to 1 %: | | 100 % | |
| | | from 1 %: | | 30 % | |
| | | NK cells | | 26 % | |
| | | PIG: IgG subclasses | | | |
| | | IgG total | | 15 % | |
| | | IgG1 | | 15 % | |
| | | IgG2 | | 15 % | |
| | | IgG3 | | 15 % | |
| | | IgG4 | | 16 % | |
| | | PRO: Specific Proteins | | | |
| | | α-1-antitrypsin | | 25 % | |
| | | α-2-macroglobulin | | 21 % | |
| | | Albumin | | 10 % | |
| | | C3 complement | | 14 % | |
| | | C4 complement | | 21 % | |
| | | Total protein | | 18 % | |
| | | Ceruloplasmin | | 19 % | |
| | | Haptoglobin | | 13 % | |
| | | IgA | | 14 % | |
| | | IgG | | 13 % | |
| | | IgM | | 18 % | |
| | | Orosomuroid | | 20 % | |
| | | Prealbumin | | 17 % | |
| | | Soluble Transferrin Receptor (sTfR) | | 20 % | |
| | | Transferrin | | 12 % | |
| | | RF: Diagnostics of Rheumatoid Arthritis and ASLO | | | |
| | | anti-streptolysin O (ASLO) | | 20 % | |
| | | TIE: Allergy Control Scheme (Total IgE) | | | |
| | | Total IgE | | 25 % | |